{"id":39435,"date":"2025-08-15T16:40:39","date_gmt":"2025-08-15T08:40:39","guid":{"rendered":"https:\/\/flcube.com\/?p=39435"},"modified":"2025-08-15T16:40:40","modified_gmt":"2025-08-15T08:40:40","slug":"minghui-pharmaceutical-secures-131m-pre-ipo-funding-led-by-orbimed-and-qiming-ventures","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39435","title":{"rendered":"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures"},"content":{"rendered":"\n

China-based Minghui Pharmaceutical Inc. announced the successful completion of a $131 million Pre-IPO financing round. The round was led by OrbiMed, a renowned global healthcare investment firm, and co-led by Qiming Venture Partners. Existing shareholder TF Capital continued its support, and the company also brought in several high-quality institutional investors, including BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment Limited. Representatives from OrbiMed and Qiming Venture Partners will join the company’s board of directors.<\/p>\n\n\n\n

Funding Utilization<\/strong>
The funds raised will primarily be used to accelerate the development of the company’s core clinical-stage programs. A key focus will be on advancing the combination therapy strategy of its PD-1\/VEGF bispecific antibody and antibody-drug conjugates (ADCs). The capital will also support the launch preparations and commercialization of the topical JAK inhibitor in China.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Minghui Pharmaceutical Inc. announced the successful completion of a $131 million Pre-IPO financing round….<\/p>\n","protected":false},"author":1,"featured_media":39436,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,2556],"class_list":["post-39435","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ipo","tag-minghui-pharmaceutical"],"yoast_head":"\nMinghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Minghui Pharmaceutical Inc. announced the successful completion of a $131 million Pre-IPO financing round. The round was led by OrbiMed, a renowned global healthcare investment firm, and co-led by Qiming Venture Partners. Existing shareholder TF Capital continued its support, and the company also brought in several high-quality institutional investors, including BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment Limited. Representatives from OrbiMed and Qiming Venture Partners will join the company's board of directors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39435\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures\" \/>\n<meta property=\"og:description\" content=\"China-based Minghui Pharmaceutical Inc. announced the successful completion of a $131 million Pre-IPO financing round. The round was led by OrbiMed, a renowned global healthcare investment firm, and co-led by Qiming Venture Partners. Existing shareholder TF Capital continued its support, and the company also brought in several high-quality institutional investors, including BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment Limited. Representatives from OrbiMed and Qiming Venture Partners will join the company's board of directors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39435\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-15T08:40:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-15T08:40:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1503-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39435#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39435\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures\",\"datePublished\":\"2025-08-15T08:40:39+00:00\",\"dateModified\":\"2025-08-15T08:40:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39435\"},\"wordCount\":152,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39435#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1503-1.webp\",\"keywords\":[\"IPO\",\"Minghui Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39435#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39435\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39435\",\"name\":\"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39435#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39435#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1503-1.webp\",\"datePublished\":\"2025-08-15T08:40:39+00:00\",\"dateModified\":\"2025-08-15T08:40:40+00:00\",\"description\":\"China-based Minghui Pharmaceutical Inc. announced the successful completion of a $131 million Pre-IPO financing round. The round was led by OrbiMed, a renowned global healthcare investment firm, and co-led by Qiming Venture Partners. Existing shareholder TF Capital continued its support, and the company also brought in several high-quality institutional investors, including BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment Limited. Representatives from OrbiMed and Qiming Venture Partners will join the company's board of directors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39435#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39435\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39435#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1503-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1503-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39435#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures - Insight, China's Pharmaceutical Industry","description":"China-based Minghui Pharmaceutical Inc. announced the successful completion of a $131 million Pre-IPO financing round. The round was led by OrbiMed, a renowned global healthcare investment firm, and co-led by Qiming Venture Partners. Existing shareholder TF Capital continued its support, and the company also brought in several high-quality institutional investors, including BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment Limited. Representatives from OrbiMed and Qiming Venture Partners will join the company's board of directors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39435","og_locale":"en_US","og_type":"article","og_title":"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures","og_description":"China-based Minghui Pharmaceutical Inc. announced the successful completion of a $131 million Pre-IPO financing round. The round was led by OrbiMed, a renowned global healthcare investment firm, and co-led by Qiming Venture Partners. Existing shareholder TF Capital continued its support, and the company also brought in several high-quality institutional investors, including BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment Limited. Representatives from OrbiMed and Qiming Venture Partners will join the company's board of directors.","og_url":"https:\/\/flcube.com\/?p=39435","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-15T08:40:39+00:00","article_modified_time":"2025-08-15T08:40:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1503-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39435#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39435"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures","datePublished":"2025-08-15T08:40:39+00:00","dateModified":"2025-08-15T08:40:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39435"},"wordCount":152,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39435#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1503-1.webp","keywords":["IPO","Minghui Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39435#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39435","url":"https:\/\/flcube.com\/?p=39435","name":"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39435#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39435#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1503-1.webp","datePublished":"2025-08-15T08:40:39+00:00","dateModified":"2025-08-15T08:40:40+00:00","description":"China-based Minghui Pharmaceutical Inc. announced the successful completion of a $131 million Pre-IPO financing round. The round was led by OrbiMed, a renowned global healthcare investment firm, and co-led by Qiming Venture Partners. Existing shareholder TF Capital continued its support, and the company also brought in several high-quality institutional investors, including BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment Limited. Representatives from OrbiMed and Qiming Venture Partners will join the company's board of directors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39435#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39435"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39435#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1503-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1503-1.webp","width":1080,"height":608,"caption":"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39435#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Minghui Pharmaceutical Secures $131M Pre-IPO Funding Led by OrbiMed and Qiming Ventures"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1503-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39435"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39435\/revisions"}],"predecessor-version":[{"id":39437,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39435\/revisions\/39437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39436"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}